World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Medicine
USA
2026

D-Index & Metrics

Best Scientists

D-Index
205
Citations
157507
World Ranking
241
National Ranking
160

Medicine

D-Index
207
Citations
161201
World Ranking
141
National Ranking
96

Research.com Recognitions

  • 2026 - Research.com Medicine in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in United States Leader Award
  • 2023 - Research.com Medicine in United States Leader Award
  • 2015 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Gabriel N. Hortobagyi is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on Medicine, with significant contributions in Biochemistry, Genetics and Molecular Biology. Within these fields, they have a strong emphasis on Oncology and Cancer Research, alongside subfields such as Pulmonary and Respiratory Medicine, Molecular Biology, and Genetics.

Their main research topics include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Breast Lesions and Carcinomas
  • PARP inhibition in cancer therapy

Gabriel N. Hortobagyi has authored numerous papers, with recent notable publications including:

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, 2023, Journal of Clinical Oncology
  • TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis, 2021, Journal of Clinical Investigation
  • Ribociclib plus Endocrine Therapy in Early Breast Cancer, 2024, New England Journal of Medicine
  • Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis, 2021, Annals of Oncology
  • Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival, 2020, JNCI Journal of the National Cancer Institute

The scientist frequently publishes in the following journals:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Oncology
  • JAMA Oncology

Regular collaborators include:

  • William E. Barlow
  • Lajos Pusztai
  • Priyanka Sharma
  • Debu Tripathy
  • Daniel F. Hayes

Gabriel N. Hortobagyi was awarded Fellow of the American Association for the Advancement of Science (AAAS) in 2015.

Best Publications

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

    Yoichi Nagata;Keng Hsueh Lan;Xiaoyan Zhou;Ming Tan

  • Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

    Benjamin D. Smith;Grace L. Smith;Arti Hurria;Gabriel N. Hortobagyi

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

    W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai

  • Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

    Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis

  • Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

    Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar

  • Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

    Rita Nahta;Dihua Yu;Mien Chie Hung;Gabriel N. Hortobagyi

  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

    Weiyi Toy;Yang Shen;Helen Won;Bradley Green

  • Overview of Resistance to Systemic Therapy in Patients with Breast Cancer

    Ana Maria Gonzalez-Angulo;Flavia Morales-Vasquez;Gabriel N. Hortobagyi

  • Treatment of breast cancer

    Gabriel N. Hortobagyi

  • Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

    Sao Jiralerspong;Shana L. Palla;Sharon Hermes Giordano;Funda Meric-Bernstam

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

    P. A. Greenberg;G. N. Hortobagyi;T. L. Smith;L. D. Ziegler

  • Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

    Bryan T. Hennessy;Ana Maria Gonzalez-Angulo;Katherine Stemke-Hale;Michael Z. Gilcrease

  • PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients.

    Keng-Hsueh Lan;Yoichi Nagata;Xiaoyan Zhou;Francisco J. Esteva

Frequent Co-Authors

Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Lajos Pusztai
Lajos Pusztai Yale University
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Ana M. Gonzalez-Angulo
Ana M. Gonzalez-Angulo The University of Texas MD Anderson Cancer Center
Massimo Cristofanilli
Massimo Cristofanilli Cornell University
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Francisco J. Esteva
Francisco J. Esteva New York University
Richard L. Theriault
Richard L. Theriault The University of Texas MD Anderson Cancer Center
Aysegul A. Sahin
Aysegul A. Sahin The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean following the path to becoming a licensed physician. There are diverse online health degree options that can lead to rewarding roles within the healthcare system. For example, a popular route is earning a cheapest online healthcare administration degree, which can prepare you for leadership roles managing hospitals or clinics, often at a lower cost and with greater flexibility.

Those seeking advanced positions may consider the masters in healthcare administration cost to find programs that are both reputable and affordable. If you’re interested in clinical leadership or research, exploring the best dnp programs online can be a smart next step for current nurses aiming for the top of their field.

For those drawn to pharmaceuticals, accredited online pharmacy school programs offer flexible pathways to becoming a Doctor of Pharmacy (PharmD). Considering these related degrees and pathways can expand your options and help you achieve your professional healthcare goals.

Best Scientists Citing Gabriel N. Hortobagyi

Trending Scientists

Recently Published Articles